{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-24-016242","form_type":"8-K","ticker":"ADCT","cik":"0001771910","company_name":"ADC Therapeutics SA","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.556701+00:00","generated_at":"2026-05-30T01:00:37.054866+00:00","sec_items":["5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"ADC Therapeutics shareholders approve capital range increase and conditional share capital amendments","bullets":["Shareholders approved amendment to Article 4a to increase capital range (52.4M for, 9.0M against).","Shareholders approved amendment to Article 4c to increase conditional share capital for financing/acquisitions (52.3M for, 9.0M against).","Amendments to articles of association became effective immediately upon approval at Nov 11, 2024 special meeting.","Broker non-votes: none reported for either proposal."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-24-016242","json":"https://secwatch.observer/filing/0000950103-24-016242.json","markdown":"https://secwatch.observer/filing/0000950103-24-016242.md","text":"https://secwatch.observer/filing/0000950103-24-016242.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000095010324016242/0000950103-24-016242-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000095010324016242/dp220630_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:00:37.054866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}